Paper38204331
Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease.
Ringdén O and 1 other. Stem Cells, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease. Papers, record 38204331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38204331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease.
- PubMed
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Graft vs Host Disease | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Mesenchymal Stem Cell Transplantation | Major topic |
| Mesenchymal Stem Cells | Major topic |
| Animals | |
| Female | |
| Humans | |
| Mice | |
| Middle Aged | |
| Rabbits | |
| Rats | |
| Acute Disease | |
| Decidua | |
| Immunosuppressive Agents | |
| Stromal Cells | |
| Infant | |
| Child, Preschool | |
| Child | |
| Adolescent | |
| Young Adult | |
| Adult | |
| Aged | |
| Clinical Trials, Phase I as Topic | |
| Clinical Trials, Phase II as Topic |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CAN 2018,419 | Swedish Cancer Society | PubMed | ||
| 111293 | Cancer Society in Stockholm | PubMed |
Source PubMed
References114
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36333233 | Immunomodulation by placenta-derived decidua stromal cells. Role of histocompatibility, accessory cells and freeze-thawing. | Cytotherapy | 2023 | https://conductscience.org/library/papers/36333233 | PubMed |
| 2 | 35853610 | Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. | Transplant Cell Ther | 2022 | https://conductscience.org/library/papers/35853610 | PubMed |
| 3 | 23307526 | Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. | Stem Cells | 2013 | https://conductscience.org/library/papers/23307526 | PubMed |
| 4 | 31817480 | Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients. | Cells | 2019 | https://conductscience.org/library/papers/31817480 | PubMed |
| 5 | 30697701 | Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. | Cochrane Database Syst Rev | 2019 | https://conductscience.org/library/papers/30697701 | PubMed |
| 6 | 18371435 | Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. | Cell Stem Cell | 2008 | https://conductscience.org/library/papers/18371435 | PubMed |
| 7 | 5654088 | Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. | Transplantation | 1968 | https://conductscience.org/library/papers/5654088 | PubMed |
| 8 | 32044400 | Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. | Biol Blood Marrow Transplant | 2020 | https://conductscience.org/library/papers/32044400 | PubMed |
| 9 | 35371003 | Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome. | Front Immunol | 2022 | https://conductscience.org/library/papers/35371003 | PubMed |
| 10 | 22966167 | Mesenchymal stem cells are injured by complement after their contact with serum. | Blood | 2012 | https://conductscience.org/library/papers/22966167 | PubMed |
| 11 | 30711482 | Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. | Trends Mol Med | 2019 | https://conductscience.org/library/papers/30711482 | PubMed |
| 12 | 11772882 | Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. | Circulation | 2002 | https://conductscience.org/library/papers/11772882 | PubMed |
| 13 | 27299362 | Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing. | Stem Cells | 2016 | https://conductscience.org/library/papers/27299362 | PubMed |
| 14 | 26765648 | Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. | Lancet Haematol | 2016 | https://conductscience.org/library/papers/26765648 | PubMed |
| 15 | 19282026 | Graft-versus-host disease. | Lancet | 2009 | https://conductscience.org/library/papers/19282026 | PubMed |
| 16 | 32320566 | Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32320566 | PubMed |
| 17 | 25162829 | Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling. | Stem Cells Dev | 2015 | https://conductscience.org/library/papers/25162829 | PubMed |
| 18 | 20130212 | Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. | J Immunol | 2010 | https://conductscience.org/library/papers/20130212 | PubMed |
| 19 | 31989101 | Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. | EClinicalMedicine | 2020 | https://conductscience.org/library/papers/31989101 | PubMed |
| 20 | 16338616 | National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. | Biol Blood Marrow Transplant | 2005 | https://conductscience.org/library/papers/16338616 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41324806 | Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/41324806 | PubMed |
| 40660274 | The rise of exosome-mediated mechanisms in MSC therapy. | J Transl Med | 2025 | https://conductscience.org/library/papers/40660274 | PubMed |
| 40515888 | Mesenchymal Stromal Cells and Graft-versus-Host Disease: Preclinical and Clinical Studies. | Stem Cell Rev Rep | 2025 | https://conductscience.org/library/papers/40515888 | PubMed |
| 39329708 | Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD. | Cells | 2024 | https://conductscience.org/library/papers/39329708 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38204331
GET https://conductscience.org/api/papers/v1/38204331/references?page=2